Trending
Elon Musk plans a Texas semiconductor factory the size of 1,000 Costco stores. Rural residents are raising infrastructure and water concerns.
Deoleo shares jumped 16% Wednesday as competing bidders escalated a takeover fight for the world’s largest olive oil bottler and marketer.
Fidelity’s FNCL beat KBE on five-year returns and charges half the fees, but State Street’s banking ETF pays a higher dividend yield.
Meta Platforms’ federal trial in California begins Tuesday with opening arguments. The proceedings are expected to last six to eight weeks.
The Situational Awareness fund had 56% in two AI stocks and 75%+ in five total when a 2026 sector correction hit. A look at what the structure exposed.
The ECB warned Monday that a U.S. tech stock correction tied to AI exuberance is likely, with limited fiscal and monetary tools available to cushion the hit.
Deoleo shares jumped 16% Wednesday as competing bidders escalated a takeover fight for the world’s largest olive oil bottler and marketer.
The ECB warned Monday that a U.S. tech stock correction tied to AI exuberance is likely, with limited fiscal and monetary tools available to cushion the hit.
Just In
Elon Musk plans a Texas semiconductor factory the size of 1,000 Costco stores. Rural residents are raising infrastructure and water concerns.
Eight-year-old Beckett Phelps is showing interest in swimming, with early guidance from Bob Bowman, the coach who built his father Michael Phelps’ career.
U.S. stocks hit a record after July inflation data showed improvement, while Asian shares fell mostly lower and U.S. futures stayed little changed.
Trump’s vaccine executive order is raising alarms among pediatricians as measles spreads, immunization rates fall, and children return to school.
Finance
Fidelity’s FNCL beat KBE on five-year returns and charges half the fees, but State Street’s banking ETF pays a higher dividend yield.
Editor's Picks
Lucid delayed its Cosmos SUV amid dwindling liquidity. The move looks like capital discipline, but raises questions about whether the company can execute its roadmap.
Latest
VanEck’s Pharma ETF offers lower costs and stability; Invesco’s Biotech ETF chases higher returns with steeper risk. Which fits your portfolio?
